Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
-
Correspondence: David W Miles david.miles@doctors.org.uk
Breast Cancer Research 2009, 11:208 doi:10.1186/bcr2237
Accesses
- Last 30 days: 127 accesses
- Last 365 days: 1329 accesses
- All time: 5970 accesses